HHS, FDA Announce Multiple Initiatives on Food Safety, Quality and Compliance Fronts

March 24, 2025

Reading Time : 2 min

In the past week, the U.S. Food and Drug Administration (FDA), in collaboration with the Department of Health and Human Services (HHS) announced three new initiatives related to food safety and food supply chain transparency. Outlined below, these new initiatives align with HHS Secretary Robert F. Kennedy Jr.’s recent announcements to focus on bolstering food safety, including the recent directive to the FDA to explore the revision of the longstanding Generally Recognized as Safe (GRAS) rule.

Operation Stork Speed

On March 18, 2025, HHS and FDA announced “Operation Stork Speed,” aimed at enhancing the safety, nutritional quality and availability of infant formula. Through this initiative, FDA plans to increase testing for heavy metals and other contaminants in infant formula. The agency is also calling on industry to “develop new infant formulas and clarify opportunities to help inform consumers about formula ingredients.” The agency states that it will use “both longstanding and newly granted” authorities to carry out its stated goals, including:

  • Issuing a Request for Information (RFI) to start a comprehensive update and review of infant formula nutrients;
  • Increasing testing for heavy metals and other contaminants in infant formula and other children foods;
  • Extending the personal importation policy; and
  • Working with both industry and consumer stakeholders to increase transparency and collaborating with the National Institutes of Health (NIH) and other scientific bodies to address scientific research gaps related to health outcomes associated with formula feeding.

Chemical Contaminants Transparency Tool for Foods

On March 20, 2025, the agency unveiled the Chemical Contaminants Transparency Tool (CCT Tool), a searchable online database that consolidates information on contaminant levels in human foods. The database lists the contaminant name, commodity, contaminant level type, level value and reference. To date, FDA has published a variety of contaminant levels for poisonous or deleterious substances in food in various guidance documents and regulations for industry. With the CCT Tool, the agency aims to consolidate this information for ease of reference. Certain contaminant levels such as allowable levels listed in the quality standard for bottled water and marine biotoxin safety levels are not included in the tool.

Extension of Compliance Date for Food Traceability Rule

Also, on March 20, 2025, the agency announced its intention to extend the compliance date for its 2022 final rule on Requirements for Additional Traceability Records for Certain Foods (Food Traceability Final Rule) by 30 months. Implementing Section 204(d) of the Food Safety Modernization Act (FSMA), the Food Traceability Rule mandates enhanced recordkeeping requirements for certain high-risk foods to improve the agency’s ability to respond to foodborne illness outbreaks and contamination events. Citing concerns among covered entities about meeting the initial compliance deadline of January 2026, FDA plans to extend the compliance date using notice and comment rulemaking at a later date. FDA intends to engage with stakeholders and assist industry with implementation.

Industry participants should expect to see further policy updates and closely monitor forthcoming guidance.

 

Share This Insight

Previous Entries

Eye on FDA

December 22, 2025

On December 18, 2025, the Food and Drug Administration (FDA) released a final guidance entitled “Processes and Practices Applicable to Bioresearch Monitoring Inspections.” The guidance was issued to comply with the Food and Drug Omnibus Reform Act of 2022, which directs FDA to issue guidance describing the processes and practices applicable to inspections of sites and facilities inspected under FDA’s Bioresearch Monitoring (BIMO) inspection program, to the extent that is not covered in already available FDA guides and manuals. The BIMO program was established to assess and monitor the conduct and reporting of FDA-regulated research as well as postmarketing activities through on-site inspections, investigations and Remote Regulatory Assessments.

...

Read More

Eye on FDA

December 15, 2025

On December 5, 2025, FDA announced its Technology-Enabled Meaningful Patient Outcomes (TEMPO) for Digital Health Devices Pilot, a new voluntary pilot that seeks to accelerate innovation and expand access to digital health devices for people living with chronic conditions. Under TEMPO, FDA will evaluate a new, risk-based enforcement approach that supports digital health devices intended for use to improve patient outcomes in cardio-kidney-metabolic, musculoskeletal and behavioral health conditions. Under the pilot, participating manufacturers may request that the agency exercise enforcement discretion for certain requirements, such as premarket authorization and investigational device requirements, while manufacturers collect and share real-world data demonstrating the device’s performance.

...

Read More

Eye on FDA

November 5, 2025

Last week, FDA released draft guidance titled “Scientific Considerations in Demonstrating Biosimilarity to a Reference Product: Updated Recommendations for Assessing the Need for Comparative Efficacy Studies.” This draft guidance reflects an evolution in FDA’s approach to determining whether a comparative clinical study with efficacy endpoints (a comparative efficacy study or CES) is necessary to support a demonstration of biosimilarity. Specifically, the agency notes that a comparative analytical assessment (CAA) is generally more sensitive when it comes to detecting differences between products than a CES.

...

Read More

Eye on FDA

October 27, 2025

On October 23, 2025, FDA released its final guidance regarding Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments. The guidance is the third guidance in a four-part series of FDA guidance focused on patient-focused drug development (PFDD) that describe how stakeholders, such as patients, caregivers, researchers, medical product developers and others can submit patient experience data and other relevant information that can be used for medical product development and regulatory decision making.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.